Effect of topical PPARβ/δ and PPARγ agonists on plaque psoriasis: A pilot study

Dermatology

Volumn 206, Issue 3, 2003, Pages 252-256

  Kuenzli, Stéphane ^a,b   Saurat, Jean Hilaire ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Nuclear hormone receptor; Peroxisome proliferator activated receptor (PPAR); Psoriasis; Rosiglitazone; Tetradecylthioacetic acid (TTA)

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; ROSIGLITAZONE; TETRADECYLTHIOACETIC ACID; UNCLASSIFIED DRUG; 1-(CARBOXYMETHYLTHIO)TETRADECANE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CELL RECEPTOR; SCAVENGER; SULFIDE; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; SKIN IRRITATION; TREATMENT OUTCOME; CLINICAL TRIAL; DRUG POTENTIATION; MIDDLE AGED; PILOT STUDY; PSORIASIS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FREE RADICAL SCAVENGERS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFIDES; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0037250963     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068897     Document Type: Article

References (42)

1. Kliewer SA, Lehmann JM, Willson TM: Orphan nuclear receptors: Shifting endocrinology into reverse. Science 1999;284:757-760.
2. Issemann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990;347: 645-750.
3. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W: Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992;68:879-887.
4. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994;91:7355-7359.
5. Zhu Y, Alvares K, Huang Q, Rao MS, Reddy JK: Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. J Biol Chem 1993;268: 26817-26820.
6. Gonzalez FJ: The role of peroxisome proliferator activated receptor alpha in peroxisome proliferation, physiological homeostasis, and chemical carcinogenesis. Adv Exp Med Biol 1997;422:109-125.
7. Rosen ED, Spiegelman BM: PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276: 37731-37734.
8. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 1996; 137:354-366.
9. Jump DB, Clarke SD: Regulation of gene expression by dietary fat. Annu Rev Nutr 1999; 19:63-90.
10. 4 pathway to inflammation control. Nature 1996;384:39-43.
11. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7:53-58.
12. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM: Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994;134:264-270.
13. Matsuura H, Adachi H, Smart RC, Xu X, Arata J, Jetten AM: Correlation between expression of peroxisome proliferator-activated receptor beta and squamous differentiation in epidermal and tracheobronchial epithelial cells. Mol Cell Endocrinol 1999;147:85-92.
14. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
15. Morikang E, Benson SC, Kurtz TW, Pershadsingh HA: Effects of thiazolidinediones on growth and differentiation of human aorta and coronary myocytes. Am J Hypertens 1997;10: 440-446.
16. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM: Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998;4:1046-1052.
17. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP: Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent anti-tumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998;58: 3344-3352.
18. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM: Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-740.
19. Michalik L, Wahli W: Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions. Curr Opin Biotechnol 1999; 10:564-570.
20. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol Cell Biol 2000;20: 5119-5128.
21. Lim H, Gupta RA, Ma WG, Paria BC, Moller DE, Morrow JD, DuBois RN, Trzaskos JM, Dey SK: Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. Genes Dev 1999;13: 1561-1574.
22. Leibowitz MD, Fievet C, Hennuyer N, Peinado-Onsurbe J, Duez H, Bergera J, Cullinan CA, Sparrow CP, Baffic J, Berger GD, Santini C, Marquis RW, Tolman RL, Smith RG, Moller DE, Auwerx J: Activation of PPARdelta alters lipid metabolism in db/db mice. FEBS Lett 2000;473:333-336.
23. Westergaard M, Henningsen J, Svendsen ML, Johansen C, Jensen UB, Schroder HD, Kratchmarova I, Berge RK, Iversen L, Bolund L, Kragballe K, Kristiansen K: Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J Invest Dermatol 2001;116:702-712.
24. Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 2001;98:5306-5311.
25. Lebwohl M, Ali S: Treatment of psoriasis. 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-498; quiz 499-502.
26. Kuenzli S, Saurat J-H: Retinoids for the treatment of psoriasis: Outlook for the future. Curr Opin Invest Drugs 2001;2:625-630.
27. Hanley K, Komuves LG, Bass NM, He SS, Jiang Y, Crumrine D, Appel R, Friedman M, Bettencourt J, Min K, Elias PM, Williams ML, Feingold KR: Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators. J Invest Dermatol 1999;113:788-795.
28. Komuves LG, Hanley K, Lefebvre AM, Man MQ, Ng DC, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR: Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 2000;115:353-360.
29. Komuves LG, Hanley K, Man MQ, Elias PM, Williams ML, Feingold KR: Keratinocyte differentiation in hyperproliferative epidermis: Topical application of PPARalpha activators restores tissue homeostasis. J Invest Dermatol 2000;115:361-367.
30. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Fluhmann B, Desvergne B, Wahli W: Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001;15:3263-3277.
31. Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W: Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice. J Cell Biol 2001;154:799-814.
32. Wahli W: Peroxisome Proliferator-Activated Receptors (PPARs): From metabolic control to epidermal wound healing. Swiss Med Wkly 2002;132:83-91.
33. Kuenzli S, Perriard J, Piguet V, Kaya G, Piletta P-A, Saurat J-H: Topical clofibrate for psoriasis. 2nd Joint Meet Int Psoriasis Symp Eur Congr Psoriasis, San Francisco, june 2001.
34. Spydevold O, Bremer J: Induction of peroxisomal beta-oxidation in 7800 C1 Morris hepa-toma cells in steady state by fatty acids and fatty acid analogues. Biochim Biophys Acta 1989; 1003:72-79.
35. Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, Williams ML, Feingold KR: Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier. J Clin Invest 1997;100:705-712.
36. Rivier M, Safonova I, Lebrun P, Griffiths CE, Ailhaud G, Michel S: Differential expression of peroxisome proliferator-activated receptor subtypes during the differentiation of human keratinocytes. J Invest Dermatol 1998;111: 1116-1121.
37. Hanley K, Komuves LG, Ng DC, Schoonjans K, He SS, Lau P, Bikle DD, Williams ML, Elias PM, Auwerx J, Feingold KR: Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J Biol Chem 2000;275:11484-11491.
38. Hanley K, Jiang Y, He SS, Friedman M, Elias PM, Bikle DD, Williams ML, Feingold KR: Keratinocyte differentiation is stimulated by activators of the nuclear hormone receptor PPARalpha. J Invest Dermatol 1998;110:368-375.
39. Rivier M, Castiel I, Safonova I, Ailhaud G, Michel S: Peroxisome proliferator-activated receptor-alpha enhances lipid metabolism in a skin equivalent model. J Invest Dermatol 2000;114:681-687.
40. Komuves LG, Hanley K, Jiang Y, Elias PM, Williams ML, Feingold KR: Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development. J Invest Dermatol 1998;111: 429-433.
41. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM: Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774.
42. Mukherjee R, Strasser J, Jow L, Hoener P, Paterniti JR Jr, Heyman RA: RXR agonists activate PPARalpha-inducible genes, lower triglycerides, and raise HDL levels in vivo. Arterioscler Thromb Vasc Biol 1998;18:272-276.